J Clin Aesthet Dermatol. 2020;13(9):33–40 by Benjeev Dhillon, MD, and Tapan Patel, MBBS Dr. Dhillon is with Define Clinic in Beaconsfield, United Kingdom. Dr. Patel is with PHI Clinic in London, United Kingdom. FUNDING: This study was funded by Allergan. DISCLOSURES: Dr. Dhillon is a former employee of Allergan, an Allergan stockholder, and a consultant
J Clin Aesthet Dermatol. 2020;13(9): E53–E58 by Thilo Gambichler, MD; Konstantina Mamali, MD; and Christina Scheel, MD Dr. Gambichler and Dr. Scheel are with the Department of Dermatology, Venereology and Allergology at Ruhr-University Bochum in Bochum, Germany. Dr, Mamali is with Cosmetic Derma Medicine in Athens, Greece. FUNDING: No funding was provided for this study.
by Carolyn I. Jacob, MD, FAAD, and Brittany Rank, PA-C Dr. Jacob and Ms. Rank are with Chicago Cosmetic Surgery and Dermatology in Chicago, Illinois. J Clin Aesthet Dermatol. 2020;13(4 Suppl):S16–S20 FUNDING: No funding was provided for the preparation of this article. DISCLOSURES: Carolyn Jacob, MD, FAAD, speaks for BTL on medical congresses. Objective: High-intensity
Dear Editor: No other single medical product has revolutionized and quite literally defined the aesthetic medicine field like botulinum toxin injections.1–5 Every year, a growing number of patients experience the cosmetic benefits of neurotoxin products as indications for use expand and new formulations are introduced into the marketplace.6 The vast clinical experience gained over the
by Davlouros Sotiris, MD; Graziano Pallotta, PhD, PharmD; Giulio Nittari, PhD, PharmD; and Francesco Amenta, MD